Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. reports developments as a clinical-stage life sciences company focused on rebalancing inflammation with its proprietary formulation Gemini. Company updates center on Gemini programs for acute kidney injury, chronic kidney disease, prevention of post-surgical infection, and severe burn-related hyperinflammation and infection.
Recurring announcements include clinical data from the PRIME study, FDA interactions tied to the AKI development pathway, advisory and conference activity, quarterly financial results, warrant inducement financings, proxy matters, and capital-structure actions such as reverse stock splits and Nasdaq listing compliance matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Revelation Biosciences Inc. (NASDAQ: REVB) reported its year-end 2022 financial results, showcasing a significant cash increase to $5.3 million, up from $1.3 million in 2021, primarily from a $15.6 million public offering. The company plans to initiate a combined Phase 1a clinical study for REVTx-100 and REVTx-300 in the latter half of 2023, supported by positive preclinical data. Revelation's net loss for 2022 was $10.8 million, or $20.09 per share, an improvement from $12.0 million in 2021, indicating reduced operational expenses. The firm anticipates sufficient funds to support operations through June 2024.
Revelation Biosciences Inc. (NASDAQ: REVB) has appointed Dr. Julia Bohannon and Dr. Antonio Hernandez to its Scientific Advisory Board. Dr. Bohannon, an Associate Professor at Vanderbilt University Medical Center, specializes in immunomodulatory treatments for burn injuries. Dr. Hernandez, also from Vanderbilt, focuses on enhancing innate immunity and developing therapies for critical care patients. Both bring significant expertise and will guide the company's PHAD-based technology for preventing and treating healthcare-associated infections. CEO James Rolke expressed excitement about their contributions to Revelation's ongoing efforts in immunologic therapies.